anti-IL-20 + placebo
Phase 1Completed 0 watching 0 views this week💤 Quiet
32
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Inflammation
Conditions
Inflammation, Rheumatoid Arthritis
Trial Timeline
Feb 1, 2010 → Dec 1, 2010
NCT ID
NCT01038674About anti-IL-20 + placebo
anti-IL-20 + placebo is a phase 1 stage product being developed by Novo Nordisk for Inflammation. The current trial status is completed. This product is registered under clinical trial identifier NCT01038674. Target conditions include Inflammation, Rheumatoid Arthritis.
Hype Score Breakdown
Clinical
10
Activity
5
Company
9
Novelty
3
Community
2
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01038674 | Phase 1 | Completed |
| NCT00818064 | Phase 1 | Completed |
| NCT01261767 | Phase 1 | Terminated |
Competing Products
20 competing products in Inflammation